Superiority of dendritic cell vaccine vs tumor cell vaccine: survival by stratification subsets in MACVAC randomized Phase II trial of patient-specific vaccines utilizing antigens from autologous melanoma tumor cell lines

ABSTRACT:

SUBMITTER: Dillman R 

PROVIDER: S-EPMC4649581 | biostudies-literature | 2015 Jan

REPOSITORIES: biostudies-literature